Biovica International AB (publ)
SSE:BIOVIC-B.ST
2.34 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Biovica International AB (publ) |
Symbool | BIOVIC-B.ST |
Munteenheid | SEK |
Prijs | 2.34 |
Beurswaarde | 182,015,262 |
Dividendpercentage | 0% |
52-weken bereik | 2.205 - 10.36 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Anders Rylander |
Website | https://www.biovica.com |
An error occurred while fetching data.
Over Biovica International AB (publ)
Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)